ISU Abxis Co. Ltd (086890) - Total Assets
Based on the latest financial reports, ISU Abxis Co. Ltd (086890) holds total assets worth ₩165.68 Billion KRW (≈ $112.28 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is ISU Abxis Co. Ltd's book value for net asset value and shareholders' equity analysis.
ISU Abxis Co. Ltd - Total Assets Trend (2014–2024)
This chart illustrates how ISU Abxis Co. Ltd's total assets have evolved over time, based on quarterly financial data.
ISU Abxis Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
ISU Abxis Co. Ltd's total assets of ₩165.68 Billion consist of 52.6% current assets and 47.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩24.94 Billion | 0.0% |
| Accounts Receivable | ₩21.36 Billion | 13.3% |
| Inventory | ₩33.06 Billion | 20.6% |
| Property, Plant & Equipment | ₩21.70 Billion | 13.6% |
| Intangible Assets | ₩28.00 Billion | 17.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how ISU Abxis Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ISU Abxis Co. Ltd (086890) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ISU Abxis Co. Ltd's current assets represent 52.6% of total assets in 2024, a decrease from 56.8% in 2014.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 23.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 20.6% of total assets.
ISU Abxis Co. Ltd Competitors by Total Assets
Key competitors of ISU Abxis Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩87.88 Billion |
|
Kolon Life Science Inc
KQ:102940
|
Korea | ₩642.14 Billion |
|
Huons Global Co. Ltd
KQ:084110
|
Korea | ₩1.47 Trillion |
ISU Abxis Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.05 | 1.47 | 6.98 |
| Quick Ratio | 1.14 | 0.90 | 3.96 |
| Cash Ratio | 0.00 | 0.55 | 0.00 |
| Working Capital | ₩38.93 Billion | ₩25.28 Billion | ₩40.35 Billion |
ISU Abxis Co. Ltd - Advanced Valuation Insights
This section examines the relationship between ISU Abxis Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.81 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -22.5% |
| Total Assets | ₩160.23 Billion |
| Market Capitalization | $83.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values ISU Abxis Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ISU Abxis Co. Ltd's assets decreased by 22.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ISU Abxis Co. Ltd (2014–2024)
The table below shows the annual total assets of ISU Abxis Co. Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩160.23 Billion ≈ $108.59 Million |
-22.50% |
| 2023-12-31 | ₩206.74 Billion ≈ $140.10 Million |
+50.61% |
| 2022-12-31 | ₩137.27 Billion ≈ $93.03 Million |
-9.15% |
| 2021-12-31 | ₩151.09 Billion ≈ $102.39 Million |
+82.59% |
| 2020-12-31 | ₩82.75 Billion ≈ $56.08 Million |
-10.80% |
| 2019-12-31 | ₩92.76 Billion ≈ $62.86 Million |
+32.82% |
| 2018-12-31 | ₩69.84 Billion ≈ $47.33 Million |
-10.19% |
| 2017-12-31 | ₩77.77 Billion ≈ $52.70 Million |
+29.96% |
| 2016-12-31 | ₩59.84 Billion ≈ $40.55 Million |
-14.52% |
| 2015-12-31 | ₩70.00 Billion ≈ $47.44 Million |
+42.88% |
| 2014-12-31 | ₩48.99 Billion ≈ $33.20 Million |
-- |
About ISU Abxis Co. Ltd
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme repla… Read more